What is the appropriate evaluation and management of an elevated dehydroepiandrosterone sulfate (DHEA‑S) level in a post‑menopausal woman?

Elevated DHEA-S in Postmenopausal Women

When DHEA-S exceeds 600 µg/dL in a postmenopausal woman, immediately obtain high-resolution adrenal CT imaging to exclude an androgen-secreting adrenal adenoma. 1

Risk Stratification by DHEA-S Level

Critical threshold (>600 µg/dL):

• This level strongly indicates an adrenal cortical adenoma and mandates urgent imaging. 1
• High-resolution adrenal CT is the required imaging modality. 2
• Do not assume benign etiology even if testosterone is normal—rare pure DHEA-S-secreting tumors exist. 2

Moderate elevation (200-600 µg/dL):

• Measure total and free testosterone in a specialized reference laboratory (early morning, fasting). 1, 2
• If testosterone is also elevated (>200 ng/dL), perform both pelvic ultrasound and adrenal CT immediately to localize the source. 2
• If testosterone is normal or mildly elevated, proceed with systematic evaluation below. 1

Mild elevation (<200 µg/dL):

• Verify with repeat measurement in a specialized laboratory. 2
• Assess for clinical signs of hyperandrogenism (hirsutism, acne, virilization). 3
• Consider physiologic variation—DHEA-S naturally declines with age but shows a transient 5-8% rise during late menopausal transition. 4, 5

Essential Clinical Assessment

Red-flag features requiring urgent work-up:

• Rapid onset or progression of androgenic symptoms (weeks to months). 2
• Virilization signs: clitoromegaly, voice deepening, increased muscle mass, male-pattern baldness. 2
• Palpable abdominal or pelvic mass on examination. 2

Pertinent history elements:

• Timing and rapidity of symptom onset (sudden vs. gradual). 2
• Exogenous androgen exposure: anabolic steroids, DHEA supplements, androgenic medications. 2
• Medication review: valproic acid raises testosterone; tamoxifen, raloxifene, and thyroid hormone raise SHBG. 6
• Glucocorticoid exposure: inhaled steroids >1 year, high-dose topical preparations, recent intra-articular injections can suppress endogenous DHEA-S. 7

Complete Hormonal Evaluation

First-line laboratory tests (early morning, fasting):

• Total and free testosterone in specialized reference laboratory. 1, 2
• 17-hydroxyprogesterone (early morning) to screen for non-classic congenital adrenal hyperplasia. 2
• SHBG to calculate free androgen index; low SHBG (<30 nmol/L) suggests metabolic syndrome or PCOS. 6
• Prolactin to exclude hyperprolactinemia. 2
• TSH and free T4 to exclude thyroid dysfunction. 2

Additional testing when indicated:

• 24-hour urinary free cortisol or overnight dexamethasone suppression test if Cushing's syndrome is suspected. 2
• ACTH stimulation test if 17-hydroxyprogesterone >200 ng/dL (stimulated level >1,000 ng/dL confirms non-classic CAH). 6
• Low-dose dexamethasone suppression test to assess adrenal androgen suppressibility. 6
• GnRH agonist challenge to differentiate ovarian from adrenal androgen sources. 6

Imaging Strategy

Mandatory imaging:

• Pelvic ultrasound is required in all cases to detect ovarian steroid-cell tumors (0.2% prevalence, >50% malignant) and assess ovarian morphology. 2
• Evaluate endometrial thickness due to chronic anovulation risk. 2

Adrenal CT indications:

• DHEA-S >600 µg/dL (absolute indication). 1
• Testosterone ≥200 ng/dL. 2
• Clinical suspicion of adrenal source despite lower hormone levels. 2

Critical Diagnostic Pitfalls

Do not assume ovarian origin solely because testosterone is elevated with high DHEA-S—ovarian tumors can co-secrete DHEA-S. 2

Do not assume adrenal origin solely because DHEA-S is elevated—rare ovarian tumors produce isolated DHEA-S excess. 2

Do not dismiss mild elevations in the context of rapid symptom progression or virilization. 2

Recognize physiologic variation: The postmenopausal ovary contributes approximately 20% of circulating DHEA-S, and a transient rise occurs during late menopausal transition. 8, 4, 5

Management Algorithm

If neoplasm is identified:

• Urgent referral to endocrinology and surgical oncology for definitive management. 2

If non-classic CAH is confirmed:

• Low-dose glucocorticoids (dexamethasone 0.25-0.5 mg nightly or prednisone 5-7.5 mg nightly) for 2-3 months. 6
• Taper after normalization and monitor every 3-4 months for 1 year. 6

If PCOS or functional hyperandrogenism is diagnosed:

• Combined oral contraceptives for menstrual regulation and androgen suppression. 6
• Anti-androgens (spironolactone 50-200 mg daily) for persistent hirsutism. 6
• Metformin (1,500-2,000 mg daily) if insulin resistance is present. 6
• Cyclic progestins (medroxyprogesterone 10 mg for 10-14 days every 1-3 months) to prevent endometrial hyperplasia if OCPs are contraindicated. 6

If isolated DHEA-S elevation without hyperandrogenism:

• Repeat measurement in 6-12 months to verify stability. 7
• Do not routinely supplement with DHEA—insufficient efficacy and safety data exist for healthy postmenopausal women. 9, 10
• DHEA supplementation may worsen depressive symptoms during menopausal transition. 11

Long-Term Monitoring

For confirmed hyperandrogenic disorders:

• Screen regularly for metabolic syndrome (type 2 diabetes, dyslipidemia, hypertension, cardiovascular disease). 2
• Ensure withdrawal bleeding at least every 3 months to reduce endometrial cancer risk. 2
• Monitor bone density if prolonged glucocorticoid therapy is required. 6

For isolated DHEA-S elevation:

• Reassess DHEA-S and testosterone every 6-12 months. 7
• Evaluate for thyroid disease, anemia, or sleep disorders if symptoms persist. 7